Repaglinide
China [CN] Repaglinide is a diabetes treatment drug, belonging to the non-sulfonylurea insulin-releasing agent class. It was successfully developed by the German company BoehringerIngelheim. In December 1997, it was approved by the US FDA. In 1998, it was successively launched in the United States and various European countries under the trade name Novolone. It is mainly used clinically to treat patients with type 2 diabetes (non-insulin-dependent) whose hyperglycemia cannot be effectively controlled by diet control, weight loss and exercise. In 2008, the US FDA approved NovoNordisk's replaglinide+metforminHCl (PrandiMet) combination tablets for marketing, for the treatment of type 2 diabetes. From the perspective of chemical structure, reateglinide is a derivative of carbamyl methylbenzoic acid and is a fast-acting and short-duration insulin secret-stimulating meter-time blood glucose regulator. Its main mechanism of action is to close the potassium channels on the β -cell membrane, causing calcium ion influx and an increase in intracellular calcium ion concentration, thereby stimulating insulin secretion.
Click enlarge Image